期刊文献+

CTP-OD1-HA和CTP-OD2-HA融合肽在K562细胞中的定位及其与BCR-ABL蛋白的相互作用 被引量:2

Location of CTP-OD1-HA and CTP-OD2-HA fusion peptide in K562 cells and its interaction with BCR-ABL protein
下载PDF
导出
摘要 目的研究CTP-OD1-HA和CTP-OD2-HA两种融合肽在慢性粒细胞白血病(CML)K562细胞中的定位及其与BCR-ABL蛋白的相互作用。方法将前期制备的CTP-OD1-HA和CTP-OD2-HA融合肽转导入K562细胞,采用免疫荧光和Western blotting方法检测其入胞情况及胞内定位,His-pull down和CoIP实验检测融合肽与BCR-ABL的相互作用。结果免疫荧光检测显示CTP-OD1-HA和CTP-OD2-HA融合肽均能穿过细胞膜进入细胞并定位于胞质,Western blotting也同时检测到进入细胞质中的两种融合肽。His-pull down实验结果表明,CTP-OD1-HA和CTP-OD2-HA融合肽在细胞外均可直接与BCR-ABL蛋白结合,CoIP实验结果显示两种融合肽在K562细胞内也能与BCR-ABL蛋白结合并形成复合物。结论 CTP-OD1-HA和CTP-OD2-HA融合肽均能成功进入白血病K562细胞并定位于细胞质,且可与BCR-ABL蛋白发生相互作用。 Objective To investigate the intracellular location of cytoplasmic transduction peptide-oligomerization domain 1-hemagglutinin (CTP-OD1-HA) and cytoplasmic transduction peptide-oligomerization domain 2-hemagglutinin (CTP-OD2-HA) fusion peptide and interaction with BCR-ABL protein in chronic myelocytic leukemia (CML) K562 cells. Methods The prepared CTP-OD1-HA and CTP-OD2-HA fusion peptide were transduced into K562 cells, and the cytoplasmic transduction peptide- oligomerization domain-hemagglutinin (CTP-OD-HA) peptide was used as positive control, and cytoplasmic transduction peptide- hemagglutinin (CTP-HA) and PBS were used as negative control. The intracellular location of the fusion peptide was demonstrated by immunotquorescence and Western blotting. The interactions between the fusion peptides and BCR-ABL protein were detected by His-pull down and CoIP test. Results Immunofluorescence assay showed that both fusion peptides CTP-OD 1-HA and CTP-OD2- HA could penetrate the cell membrane, and they were mainly localized in cytoplasm. Western blotting also confirmed the existence of the two fusion peptides in the cytoplasm. His-pull down showed that CTP-OD1-HA and CTP-OD2-HA could directly bind BCR- ABL protein outside the cells, and CoIP experiment showed that both fusion peptides could interact with BCR-ABL protein and form complex in the K562 cells. The negative control CTP-HA fusion peptide and PBS showed no such effects. Conclusion CTP- OD1-HA and CTP-OD2-HA fusion peptides can successfully target into CML K562 cells and locate in cytoplasm, and it interacts with BCR-ABL protein.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2013年第11期896-899,共4页 Medical Journal of Chinese People's Liberation Army
基金 国家自然科学基金(30670901 30871102)~~
关键词 白血病 单核细胞 慢性 融合蛋白质类 bcr-abl leukemia, myelomonocytic, chronic fusion proteins, bcr-abl
  • 相关文献

参考文献3

二级参考文献24

  • 1孟凡义,扶云碧.白血病细胞表面分子抗原的靶向治疗[J].中华医学杂志,2005,85(7):441-443. 被引量:2
  • 2de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia:incidence of sus- tained responses in an intention-to-treat analysis [ J 1. J Clin Oncol, 2008,26:3358 - 3363.
  • 3Larson RA, Druker B J, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia:a subanalysis of the IRIS study [ J ]. Blood ,2008, 111:4022 -4028.
  • 4Baccarani M, Castagnetti F, Gugliotta G, et al. European Leukemia netresponse definitions and European |eukemianet management rec- ommendations [ J ]. Best Pract Res Clin Haematol, 2009,22 ( 3 ) : 331 -341.
  • 5Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacody- namics of imatinib in a phase I trial with chronic myeloid leukemia patient [ J ]. J Clin Oncol,2004,22:935 - 942.
  • 6Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR- ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic re- sponse[ J]. Clin Cancer Res ,2007,13:6136 - 6143.
  • 7Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with cytogenetic and molecular responses to standard- dose imatinib in chronic myeloid leukemia [ J ]. Blood, 2007,109 : 3496 - 3499.
  • 8Sang KS, Suk JO, Byung SK, et al. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treat- ment with standard dose of imatinib in newly diagnosed chronic my- eloid leukemia [ J ]. Leukemia & Lymphoma, 2011,52 : 1024 - 1029.
  • 9Takahashi N, Wakita H, Miura M, et al. Correlation between imatinib pharmackinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia [ J 1. Clin Pharmacology & Therapeutics ,2010,88:809 - 813.
  • 10Hughes TP,Kaeda J,Brandford S,et al.Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chroninc myeloid leukemia.N Engl J Med,2003,349(15):1421

共引文献4

同被引文献19

  • 1齐静,彭晖,顾振纶,梁中琴,杨纯正.伊马替尼耐药的K562细胞系的建立及其生物学特性研究[J].中华血液学杂志,2004,25(6):337-341. 被引量:20
  • 2Wang Y, Waldron TR, Dhaka A, et al. The Ras effector RIN1 derectly competes with RAF and is regulated by 14-3-3 proteins [J]. Mol Cell Biol, 2002, 22(3): 916-926.
  • 3Bliss JM, Venkatesh B, ColicelliJ. The RIIq family of Ras effectors[J]. Methods Enzymol, 2006, 407: 335-344.
  • 4Hu H, Bliss JM, Wang Y~ et al. RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration[J]. Curr Biol, 2005, 15(9): 815-823.
  • 5Cao X, Tanis KOa Koleske AJ, et al. Enhancemnt ofABL kinase catalytic efficiency by a direct binding regulator is independent of other regulatory mechanisms [J]. J Biol Chem, 2008, 283 (46): 31401-31407.
  • 6Younos IH, Dafferner AJ, Gulen D, et al. Tumor regulation of myeloid-derived suppressor cell proliferation and trafficking [J]. Int Immunopharmacol, 2012, 13(3): 245-256.
  • 7Chmine K, Nagai T, Tarumoto T, et al. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/ SR[J]. Stem Cells, 2003, 21(3): 315-321.
  • 8Thai M, Ting PYj McLaughlin J, et al. ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1 [J]. Leukemia, 2011, 25(2): 290-300.
  • 9Tala I~ Chen R, Hu T, et al. Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression[J]. Leukemia, 2013, 27(5): 1080-1089.
  • 10Patel H, Marley SB, Gordon MY. Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2[J]. Genes Chromosomes Cancer, 2006, 45(12): 1121-1129.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部